Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.1487
- Book/Share 37.7947
- PB 9.3335
- Debt/Equity 0.5906
- CurrentRatio 0.784
- ROIC 0.3934
- MktCap 1567501674741.4292
- FreeCF/Share 13.9401
- PFCF 25.2868
- PE 14.1233
- Debt/Assets 0.2059
- DivYield 0.0303
- ROE 0.7786
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
News
Novo Nordisk: The Fear Is Overblown
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk's about 55% stock decline since June 2024 is driven by clinical trial misses, increasing competition, and geopolitical turbulence. Due to the compressed valuation, Novo Nordisk needs to grow in the mid-single digit range to justify the current valuation. Considering realistic growth rates, the company could be undervalued by 50+%.
Read More
Hims & Hers stock price soars after partnership with Novo Nordisk to offer weight-loss drug Wegovy
Published: April 30, 2025 by: Fast Company
Sentiment: Positive
Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordisk. That partnership will see Hims & Hers offer Novo Nordisk's weight-loss drug Wegovy through its platform.
Read More
Why New Wegovy Deals Won't Restore Novo Nordisk's Obesity Lead
Published: April 30, 2025 by: WSJ
Sentiment: Negative
The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only getting wider.
Read More
Growth Is Priced Out Of Novo Nordisk
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Negative
A lot went wrong for Novo Nordisk A/S in the last six months, and a lot went right for competitor Eli Lilly. Novo Nordisk's competitive positioning in the obesity market has worsened, but I believe the market has overshot to the downside. Not all is lost, and there are additional efforts the company is making to stay relevant, ranging from new trials of CagriSema and higher doses of semaglutide, to external innovation.
Read More
Hims & Hers stock pops on Novo Nordisk partnership
Published: April 29, 2025 by: Proactive Investors
Sentiment: Positive
Hims & Hers (NYSE:HIMS) shares surged after it announced a partnership with Novo Nordisk that will allow it to offer the drugmaker's weight loss product Wegovy through its telehealth platform. Investors welcomed the collaboration, which positions Hims & Hers to participate directly in the fast-growing market for GLP-1 weight-loss drugs.
Read More
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Published: April 29, 2025 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S NVO and Hims & Hers Health, Inc. HIMS announced a long-term collaboration on Tuesday.
Read More
Pharma firms maastraz
Published: April 29, 2025 by: CNBC International TV
Sentiment: Neutral
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
Read More
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
Read More
Hims & Hers partners with Novo Nordisk to sell Wegovy
Published: April 29, 2025 by: Fox Business
Sentiment: Positive
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Read More
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price. The deal is a game changer, enabling Hims to offer Wegovy at $599/month versus $1,999/month. I think this deal hints at potential to do the same with Ozempic further boosting the stock, which is already up +30% in pre-market trading.
Read More
White House Slams AMZN, HIMS & NVO Wegovy Partnership, SOFI Rallies
Published: April 29, 2025 by: Schwab Network
Sentiment: Negative
Amazon (AMZN) shares faced selling pressure after the White House called the company's decision to display tariff costs on products a "hostile and political act." Diane King Hall notes it's just the latest company following a formula.
Read More
Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar
Published: April 29, 2025 by: WSJ
Sentiment: Positive
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.
Read More
Novo Nordisk's obesity drug Wegovy debuts in Thailand
Published: April 28, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's local subsidiary said on Monday, marking the injectable drug's first entry into the Southeast Asian market.
Read More
Why Novo Nordisk Stock Dropped Today
Published: April 25, 2025 by: The Motley Fool
Sentiment: Negative
Novo Nordisk (NVO -1.68%), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m. ET Friday after suffering a one-two punch from Reuters and a bank analyst.
Read More
Why Novo Nordisk Stock Popped Today
Published: April 22, 2025 by: The Motley Fool
Sentiment: Positive
Novo Nordisk (NVO 2.71%), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another shot in the arm yesterday -- one that helped the stock dodge the market downturn entirely and end the day somewhat in the green. The same news that helped Novo stock out yesterday, moreover, is today turning into solid gains as Novo Nordisk stock rises 2.5% through 11 a.m.
Read More
Novo Nordisk: Be Greedy When Others Are Fearful
Published: April 22, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk is a high-quality biopharma company with a strong diabetes franchise and a booming obesity drug segment, making it an attractive growth play. Following a 50% drop from recent highs, NVO trades at a significant discount compared to historical valuations, presenting a buying opportunity. The company's diverse portfolio, including diabetes, obesity, and rare diseases, ensures robust growth and reduces reliance on any single product.
Read More
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Published: April 22, 2025 by: The Motley Fool
Sentiment: Positive
Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NVO 0.48%), the once-obscure Danish company that earned the first U.S. Food and Drug Administration (FDA) approval for such treatments with its Wegovy back in mid-2021.
Read More
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill
Published: April 22, 2025 by: WSJ
Sentiment: Negative
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots.
Read More
Down 60%, Is This Growth Stock Too Cheap to Ignore?
Published: April 22, 2025 by: The Motley Fool
Sentiment: Positive
In this video, I will cover recent updates regarding Novo Nordisk (NVO 0.48%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Read More
Is Novo Nordisk falling behind Eli Lilly in the weight-loss drug race?
Published: April 22, 2025 by: Invezz
Sentiment: Neutral
Danish drugmaker Novo Nordisk A/S (CPH: NOVO-B) lost more than 10% last week after its US rival Eli Lilly & Co (NYSE: LLY) reported encouraging Phase 3 data for its oral weight-loss treatment. Lilly's orforglipron demonstrated “statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines” in the late-stage clinical trial.
Read More
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)
Published: April 21, 2025 by: 24/7 Wall Street
Sentiment: Negative
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Read More
Novo Nordisk: A Price Too Low To Ignore
Published: April 18, 2025 by: Seeking Alpha
Sentiment: Positive
Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is disappointing results for its drug trials, though challenges like potential tariffs on Denmark, its home country, also play a part. Yet, the company's robust fundamentals, healthy outlook and attractive market multiples go in its favour, justifying a Buy rating.
Read More
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
Read More
The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now
Published: April 15, 2025 by: Seeking Alpha
Sentiment: Positive
Unprecedented Opportunities: Recent market panic has created deep discounts among world-class blue-chip companies trading at 52-week lows, offering up to 100% potential returns and secure yields approaching 8%. Trade War Realities: Despite severe pessimism driven by historic tariff increases (highest since 1909), the actual economic impact might be significantly less dire, potentially avoiding recession altogether. Institutional strategies, such as pensions and risk parity funds, may soon trigger substantial stock-buying due to automatic rebalancing. This would provide strong support and fuel market rallies from oversold conditions.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
Novo Nordisk warns consumers about counterfeit versions of Ozempic in US
Published: April 14, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk said on Monday it has become aware of several hundred units of counterfeit versions of its diabetes drug Ozempic being distributed outside its authorized supply chain in the United States.
Read More
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Published: April 14, 2025 by: The Motley Fool
Sentiment: Positive
Bad news for Pfizer (PFE 1.07%) turned into good news for Eli Lilly (LLY 2.42%), Novo Nordisk (NVO 2.23%), and Viking Therapeutics (VKTX 8.48%) Monday morning, each of which is rising on Pfizer's latest product announcement.
Read More
We see about 50% upside on Novo Nordisk, but there are risks, says strategist
Published: April 11, 2025 by: CNBC International TV
Sentiment: Positive
Michael Field, chief EMEA equity strategist at Morningstar, discusses European stocks amid tariff uncertainty.
Read More
Here's Why Novo Nordisk (NVO) is a Strong Value Stock
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406